(Q46965253)

English

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

scientific article published on 5 October 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial (English)

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

diabetic macular edema

1 reference

based on heuristic

inferred from title

author name string

Hamid Ahmadieh

1

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

Alireza Ramezani

2

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

Nasser Shoeibi

3

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

Bijan Bijanzadeh

4

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

Ali Tabatabaei

5

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

Mohsen Azarmina

6

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

Masoud Soheilian

7

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

Gholamreza Keshavarzi

8

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

Mohammad-Reza Mohebbi

9

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

publication date

5 October 2007

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

Graefe's Archive for Clinical and Experimental Ophthalmology

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

246

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

4

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

483-489

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

https://scigraph.springernature.com/pub.10.1007/s00417-007-0688-0

0 references

The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00417-007-0688-0

21 January 2018

Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results

1 reference

https://api.crossref.org/works/10.1007%2FS00417-007-0688-0

21 January 2018

Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate

1 reference

https://api.crossref.org/works/10.1007%2FS00417-007-0688-0

21 January 2018

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VEGF-initiated blood-retinal barrier breakdown in early diabetes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal triamcinolone for refractory diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of intravitreal bevacizumab (Avastin)

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/17917738

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00417-007-0688-0

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17917738

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46965253&oldid=2140101369"